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Sufentanil is a new analogue of fentanyl which is approximately five to ten times more potent, t While its pharmacokinetics have been extensively studied in patients undergoing various surgical procedures, 2 they have not been determined in patients undergolng renal transplantation. There are several characteristics in these patients which may be associated with pharmacokinetic alterations. These include plasma protein changes and consequent alterations in drug binding, 3''* intravascular and extravascular volume alterations, electrolyte abnormalities and other physiologic derangements induced by chronic renal failure and/or chronic haemodialysis. In light of these characteristics, this study was undertaken to define the pharmaeekinetie profile of sufentanil during renal transplantation.
Methods
Ten patients scheduled for kidney transplantation were included in this study. All patients provided written infomled consent and the study protocol was approved by the Human Investigations Committee. All patients were in chronic renal failure and were undergoing haemodialysis three times per week. None had a history of liver disease or congestive heart failure. Patients received a kidney transplant from a living related or a cadaveric donor. Premedication consisted of diazepam 5-10 mg PO approximately 90 minutes prior to surgery.
Upon arrival in the operating room a peripheral 1V and a central venous line were inserted under local anaesthesia. General anaesthesia was induced with thiopentone 5-7 mg' kg -t IV, while the patient was breathing 100 per cent oxygen. Tracheal [ntubation was facilitated by atracufium 0.4 mg-kg IV. Anaesthesia was maintained with isoflurane 0.5-1.0 per cent (inspired concentration), as needed and nitxous oxide:oxygen 50:50. When the blood pressure and pulse stabilized, sufentanil 2.0/a,g. kg-I was administered through the peripheral IV over a ten second period. Blood samples for sufentanil assay were obtained from the central venous line at 1, 3, 5, 7, 10, 15, 20, 30 , and 60 minutes and hourly for six hours after drug administration, and at extubation. Time from sufentanil administration until the patients were extubated was also recorded. Plasma samples were separated and frozen until sufentanil plasma concentrations were measured using radioimmunoassay. A commercially available kit was used which had a sensitivity of 0.1 ng. ml-~ and a variability of six to ten per cent. Tritium-labelled material was used for the assay. Plasma drug concentration vs time relationships for each patient were graphically fitted to both a bi-and triexponentlal equation using weighted, nonlinear least squares regression analysis. Results were expressed as mean ---SEM. Derivations of pharmacokinetic parameters were in accordance with formulae described previously: Respiratory status was monitored by clinical observation. If respiratory rate was eight breaths-min -~ or less the patient was considered to have respiratory depression.
Results
A total of ten patients were studied. All were on chronic dialysis prior to surgery. Seven patients received kidney transplants from living related donors and three from r donors. All patients were male. The mean age was 39 ---0.45 years and mean weight was 67.5 ---1.3 kg. Both bi-and triexponential equations described plasma decay curves well, with the biexponential equation providing the best fit. 6 As seen in the Figure, initial plasma sufentanil concentrations decreased rapidly. After 30 minutes, the plasma decay of sufentanil occurred at a much slower rate. Approximately 180 minutes alter sufentanil administration, a transient increase in plasma sufentanil concentration was noted in six of the ten patients. Beyond 180 minutes, elimination proceeded at an extremely slow rate. Pharmacokinetie data are listed in the Table. The mean -SEM half lives for the alpha and beta phases were 2.9 ---1.3 minutes and 176 -'-87 minutes, respectively. The volume of distribution in the 
Discussion
The pharmacokinetie data for each patient were best described using a biexponential equation. This is in agreement with sufentanil pharmacokinetic data repotted in elderly patients 7 and burn patients, s However, another group of investigators found that a triexponential equation provided the best fit for sufentanil data in healthy surgical patients undergoing various surgical procedures. 2 There are several factors which may explain why a two-compartment model best accommodated the data in this study and a three-compartment model best fit the data in normal patients, Organ perfusion, volume status and drug protein binding are important determinants of drug distribution and elimination. In renal failure patients each of these can be markedly altered, For instance, lack of kidney peffusien may decrease volume of distribution. Volume status is also greatly modified by haemodialysis and anuric renal failure. Depending on how recently dialysis occurred, patients may be either hypovolaemic or overhydrated.
Various studies have documented abnormal protein binding in uremic patients. 9.m There is evidence to suggesl that these abnormalities are due, at least in part, to a qualitative defect rather than a quantitative defect in plasma proteins, lj-~a The pharmacokinetic alterations attendant to these abnormalities in renal failure patients may explain why sufentanil pharmaeokinetics fit best to a biexponential curve. Nevertheless, central compartment volume of distribution (Vc), the terminal elimination half life and total drug clearance in our patients were almost identical to the values reported for healthy patients where the triexponenti',d expression was employed. 2 The volume of distribution (Vd beta), however, was much smaller in our study and was the only parameter which was substantially different from values derived in previous sufentanil studies. 2'7"s It is likely that this Vd beta difference resulted from the transient increase in sufentanil concentrations that occurred in many patients close to the time of revascularization of the implanted kidney and reperfnsion of the lower extremity. Sufentanil which had been deposited in the legs may have been "washed" back into the circulation. The equalion used to generate the Vd beta value depends on the terminal elimination slope (i.e., beta), which was influenced by the sudden, although slight, increase in the sufentanil concentration. Also, with reference to the terminal exponential function, apparent plasma sufentanil concentration decay was extremely slow. This may he attributed to the relatively short sampling time. Additional points beyond 360 minutes may have resulted in a better characterization of elimina-
tion,
Prolonged respiratory depression occurred in only one out of ten patients and this lasted for nine hours. In view of miotie pupils and the fact that adequate neuromuscular transmission was present as assessed by a nerve stimulator, sufentanil was the most likely cause of this respiratory depression. However, it is possible that isoflurane was a contributing factor. All other patients were extubated within approximately 45 minutes after arrival in the Recovery Room. None of the patients received an opioid antagonist or required reintubation. Although we did not have a control group to compare the duration of sufentanilassociated respiratory depression, clinically this was not a problem_ This is further emphasized by the fact Ihat virtually all patients received low concentrations of isoflurane, an agent which may have potentiated naycoticinduced hypotension.
In conclusion, sufentanil phanrmeokinetics in patients undergoing renal transplantation arc similar to those reported in healthy patients. This suggests that the kidney plays little, if any, role in the drug's distribution and elimination. Accordingly, adjustments in sufentanil doses appear to be unnecessary when anaesthetizing renal transplant patients. Since these patients had functioning kidneys for the latter part of the study, it should be emphasized that these findings may not apl~ly to patients with renal failure that is not remedied. 
